BVNRY:OTCMKTS
Bavarian Nordic A/S - ADR
$11.09
arrow_downward
-0.05%(-0.0050) 1D
Oct 7, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BVNRY...
Open
$10.96
High
$11.09
Low
$10.96
Mkt. cap
2.64B
Avg. vol.
2.49K
Volume
1.08K
P/E ratio
11.85
52-wk high
$13.00
52-wk low
$8.67
EPS
$0.94
Beta
1.45
Shares outstanding
237.82M
No. of employees
2K
Open
$10.96
High
$11.09
Low
$10.96
Mkt. cap
2.64B
Avg. vol.
2.49K
Volume
1.08K
P/E ratio
11.85
52-wk high
$13.00
52-wk low
$8.67
EPS
$0.94
Beta
1.45
Shares outstanding
237.82M
No. of employees
2K
News stories
From web sources and news partners
Mitrade
·
7 minutes ago
Strip Out AI and the S&P 500 Looks Very Different, Goldman Index Shows
JournalArta
·
8 minutes ago
S&P 500 posts first close above 7,800: Full Details
StoneX
·
9 hours ago
Dow Jones Forecast: Caution Persists Ahead of the Fed Minutes
BigGo Finance
·
3 hours ago
US Treasury Yields Hit 24-Year High, Dow Drops 341 Points, TSMC ADR Falls Over 2%
Profile
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
About Bavarian Nordic A/S - ADR
CEOPaul Chaplin
Employees1.91K
FoundedJul 1, 1992
Headquarters-
SectorBiotechnology
Websitebavarian-nordic.com